Physician profile
Brian S Sheets
NPI 1023171204
$345.73
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.51 · 2020: $102 · 2021: $73.48 · 2022: $98.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $76.55 | 2019-2022 | |
| Abbvie INC. | $76.39 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.51 | 2021 | |
| Lilly USA, LLC | $27.06 | 2020 | |
| Mayne Pharma Commercial LLC | $24.68 | 2022 | |
| Amarin Pharma, INC. | $22.79 | 2020 | |
| Bausch Health US, LLC | $19.92 | 2019 | |
| Neos Therapeutics, Lp | $18.43 | 2019 | |
| Eisai INC. | $17.16 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.83 | 2019 | |
| Csl Behring | $11.41 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Sheets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.